Europäische Union - Estnisch - EMA (European Medicines Agency)

intervet international b.v. - sead circovirus tüüp 2 (pcv2) orf2 allüksuste antigeeni, mycoplasma hyopneumoniae j inaktiveeritud tüvi - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sead (nuumamiseks) - aktiivse immuniseerimise sigade vähendada viraemia, viirus koormus (kopsud ja lümfoidse koe, viiruse levikuga põhjustatud sigade circovirus tüüp 2 (pcv2) infektsiooni ja raskuse kopsu kahjustused põhjustavad mycoplasma hyopneumoniae infektsioon. et vähendada mycoplasma hyopneumoniae ja / või pcv2 infektsioonide ilmnemist viimistlusperioodi jooksul (nagu on täheldatud välitingimustes).

Europäische Union - Estnisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europäische Union - Estnisch - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immuunsuse tekkekohad on tõestatud 1 nädala jooksul pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse ja chlamydophila felis komponentide jaoks. immuunsuse kestus on 1 aasta pärast viimast (uuesti) vaktsineerimist.

Europäische Union - Estnisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Estnisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immuunsuse tagajärgi on tõestatud üks nädal pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse, chlamydophila felis ja panleukopeenia komponentide jaoks. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Estnisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Estnisch - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, hepatitis b surface antigen, bordetella pertussis (inactivated), tetanus toxoid - hepatitis b; tetanus; immunization; whooping cough; diphtheria - vaktsiinid - tritanrix hepb on näidustatud aktiivseks vaktsineerimiseks difteeria, teetanuse, läkaköha ja hepatiit b (hbv) vastu kuue nädala vanustel lastel (vt lõik 4.

Europäische Union - Estnisch - EMA (European Medicines Agency)

zoetis belgium sa - sead circovirus vaktsiin (inaktiveeritud, rekombinantse) - immunologicals for suidae, inactivated viral vaccines - sead (nuumamiseks) - aktiivse immuniseerimise sigade alates 3 elunädalast vastu sead circovirus tüüp 2 (pcv2), et vähendada viiruse koormus vere ja lümfisüsteemi kudede ja fekaalse kadumas põhjustatud infektsiooni pcv2.

Estland - Estnisch - Ravimiamet

sanofi pasteur - gripiviirus, inaktiveeritud, tükeldatud viirus või pinnaantigeen - süstesuspensioon süstlis - 1annus 0.5ml 0.5ml 50tk; 1annus 0.5ml 0.5ml 10tk; 1annus 0.5ml 0.5ml 1tk; 1annus 0.5ml 0.5ml 20tk

Estland - Estnisch - Ravimiamet

sanofi pasteur - gripiviirus, inaktiveeritud, tükeldatud viirus või pinnaantigeen - süstesuspensioon süstlis - 1annus 0.5ml 0.5ml 20tk; 1annus 0.5ml 0.5ml 1tk; 1annus 0.5ml 0.5ml 10tk